Browse RNF146

Summary
SymbolRNF146
Namering finger protein 146
Aliases DKFZp434O1427; dactylidin; dJ351K20.1; iduna; E3 ubiquitin-protein ligase RNF146
Chromosomal Location6q22.1-q22.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytosol. Nucleus. Note=Translocates to the nucleus after DNA damage, such as laser-induced DNA breaks, and concentrates at DNA breaks. This translocation requires PARP1 activation and PAR-binding.
Domain PF02825 WWE domain
Function

E3 ubiquitin-protein ligase that specifically binds poly-ADP-ribosylated (PARsylated) proteins and mediates their ubiquitination and subsequent degradation. May regulate many important biological processes, such as cell survival and DNA damage response. Acts as an activator of the Wnt signaling pathway by mediating the ubiquitination of PARsylated AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex. Acts in cooperation with tankyrase proteins (TNKS and TNKS2), which mediate PARsylation of target proteins AXIN1, AXIN2, BLZF1, CASC3, TNKS and TNKS2. Recognizes and binds tankyrase-dependent PARsylated proteins via its WWE domain and mediates their ubiquitination, leading to their degradation. Different ubiquitin linkage types have been observed: TNKS2 undergoes ubiquitination at 'Lys-48' and 'Lys-63', while AXIN1 is only ubiquitinated at 'Lys-48'. May regulate TNKS and TNKS2 subcellular location, preventing aggregation at a centrosomal location. Neuroprotective protein. Protects the brain against N-methyl-D-aspartate (NMDA) receptor-mediated glutamate excitotoxicity and ischemia, by interfering with PAR-induced cell death, called parthanatos. Prevents nuclear translocation of AIFM1 in a PAR-binding dependent manner. Does not affect PARP1 activation (By similarity). Protects against cell death induced by DNA damaging agents, such as N-methyl-N-nitro-N-nitrosoguanidine (MNNG) and rescues cells from G1 arrest. Promotes cell survival after gamma-irradiation. Facilitates DNA repair.

> Gene Ontology
 
Biological Process GO:0000209 protein polyubiquitination
GO:0016055 Wnt signaling pathway
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:0051865 protein autoubiquitination
GO:0060070 canonical Wnt signaling pathway
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0070936 protein K48-linked ubiquitination
GO:0090263 positive regulation of canonical Wnt signaling pathway
GO:0198738 cell-cell signaling by wnt
Molecular Function GO:0004842 ubiquitin-protein transferase activity
GO:0016874 ligase activity
GO:0019787 ubiquitin-like protein transferase activity
GO:0061630 ubiquitin protein ligase activity
GO:0061659 ubiquitin-like protein ligase activity
GO:0072572 poly-ADP-D-ribose binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-4641257: Degradation of AXIN
R-HSA-5688426: Deubiquitination
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-162582: Signal Transduction
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
R-HSA-5689880: Ub-specific processing proteases
Summary
SymbolRNF146
Namering finger protein 146
Aliases DKFZp434O1427; dactylidin; dJ351K20.1; iduna; E3 ubiquitin-protein ligase RNF146
Chromosomal Location6q22.1-q22.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RNF146 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRNF146
Namering finger protein 146
Aliases DKFZp434O1427; dactylidin; dJ351K20.1; iduna; E3 ubiquitin-protein ligase RNF146
Chromosomal Location6q22.1-q22.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RNF146 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.6 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolRNF146
Namering finger protein 146
Aliases DKFZp434O1427; dactylidin; dJ351K20.1; iduna; E3 ubiquitin-protein ligase RNF146
Chromosomal Location6q22.1-q22.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RNF146 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0060.979
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0830.963
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0670.958
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0340.947
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3710.831
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5430.799
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0880.794
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1050.944
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0550.973
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3670.774
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1480.542
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0750.194
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RNF146 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRNF146
Namering finger protein 146
Aliases DKFZp434O1427; dactylidin; dJ351K20.1; iduna; E3 ubiquitin-protein ligase RNF146
Chromosomal Location6q22.1-q22.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RNF146. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRNF146
Namering finger protein 146
Aliases DKFZp434O1427; dactylidin; dJ351K20.1; iduna; E3 ubiquitin-protein ligase RNF146
Chromosomal Location6q22.1-q22.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RNF146. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RNF146.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRNF146
Namering finger protein 146
Aliases DKFZp434O1427; dactylidin; dJ351K20.1; iduna; E3 ubiquitin-protein ligase RNF146
Chromosomal Location6q22.1-q22.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RNF146. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRNF146
Namering finger protein 146
Aliases DKFZp434O1427; dactylidin; dJ351K20.1; iduna; E3 ubiquitin-protein ligase RNF146
Chromosomal Location6q22.1-q22.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RNF146 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRNF146
Namering finger protein 146
Aliases DKFZp434O1427; dactylidin; dJ351K20.1; iduna; E3 ubiquitin-protein ligase RNF146
Chromosomal Location6q22.1-q22.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RNF146 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRNF146
Namering finger protein 146
Aliases DKFZp434O1427; dactylidin; dJ351K20.1; iduna; E3 ubiquitin-protein ligase RNF146
Chromosomal Location6q22.1-q22.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RNF146 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.